Characteristics of patients and grafts
Characteristics . | Bone marrow transplantation, n = 45 . | Cord blood transplantation, n = 68 . | P* . |
|---|---|---|---|
| Age, y | < .01 | ||
| Median | 26 | 36 | |
| Range | 16-50 | 16-53 | |
| Weight, kg | .01 | ||
| Median | 59.6 | 55.1 | |
| Range | 37.2-84.6 | 36.2-76.2 | |
| Sex, no. (%) | .65 | ||
| Male | 30 (67) | 42 (62) | |
| Female | 15 (33) | 26 (38) | |
| CMV serologic status, no. (%) | .07 | ||
| Negative | 12 (27) | 9 (13) | |
| Positive | 33 (73) | 59 (87) | |
| Diagnosis, no. (%) | < .01 | ||
| AML | |||
| CR1, CR2 | 5 (11) | 15 (22) | |
| Advanced | 10 (22) | 24 (35) | |
| ALL | |||
| CR1, CR2 | 4 (9) | 6 (9) | |
| Advanced | 4 (9) | 9 (13) | |
| CML | |||
| CP | 7 (16) | 1 (1)† | |
| Advanced | 11 (24) | 4 (6) | |
| MDS | |||
| RA | 3 (7) | 3 (4) | |
| Advanced | 1 (2) | 4 (6) | |
| NHL | |||
| CR1, CR2 | 0 | 3 (4)† | |
| Advanced | 0 | 0 | |
| Duration from diagnosis to transplantation, mo | .06 | ||
| Median | 20 | 17 | |
| Range | 4-146 | 3-148 | |
| Duration of donor search, mo | < .01 | ||
| Median | 11 | 3 | |
| Range | 4-52 | 1-36 | |
| Conditioning, no. (%)‡ | .60 | ||
| TBI + Ara-C/G-CSF + CY | 36 (80) | 49 (72) | |
| TBI + CY | 5 (11) | 12 (18) | |
| TBI + α | 4 (9) | 7 (10) | |
| GVHD prophylaxis, no. (%) | < .01 | ||
| CsA | 0 | 3 (4) | |
| CsA + sMTX | 23 (51) | 65 (96) | |
| FK506 + sMTX | 21 (47) | 0 | |
| CsA + mPSL | 1 (2) | 0 | |
| G-CSF administration on first 7days, no. (%) | < .01 | ||
| Yes | 39 (87) | 68 (100) | |
| No | 6 (13) | 0 | |
| Year of transplantation, no. (%) | < .01 | ||
| 1997-1999 | 33 (73) | 9 (13) | |
| 2000-2003 | 12 (27) | 59 (87) | |
| Follow-up time, mo | .77 | ||
| Median | 14 | 25.2 | |
| Range | 1-100 | 1-68 | |
| Follow-up time in survivors, mo | < .01 | ||
| No. of evaluable patients | 21 | 52 | |
| Median | 59 | 26 | |
| Range | 13-100 | 4-68 | |
| No. of leukocytes for transplantation, × 107/kg | < .01 | ||
| Median | 33.0 | 2.47 | |
| Range | 6.6-50 | 1.1-5.29 | |
| No. of HLA-A, -B, and -DRB1 mismatches, no. (%) | < .01 | ||
| 0 | 39 (87) | 0 | |
| 1 | 6 (13) | 14 (21) | |
| 2 | 0 | 37 (54) | |
| 3 | 0 | 15 (22) | |
| 4 | 0 | 2 (3) | |
| Sex of donor/recipient, no. (%) | .22 | ||
| Male/male | 22 (49) | 21 (31) | |
| Female/female | 5 (11) | 10 (15) | |
| Female/male | 8 (18) | 21 (31) | |
| Male/female | 10 (22) | 16 (24) | |
| Extent of ABO match, no. (%) | .75 | ||
| Match | 16 (36) | 20 (29) | |
| Minor mismatch | 11 (24) | 20 (29) | |
| Major mismatch | 18 (40) | 28 (41) |
Characteristics . | Bone marrow transplantation, n = 45 . | Cord blood transplantation, n = 68 . | P* . |
|---|---|---|---|
| Age, y | < .01 | ||
| Median | 26 | 36 | |
| Range | 16-50 | 16-53 | |
| Weight, kg | .01 | ||
| Median | 59.6 | 55.1 | |
| Range | 37.2-84.6 | 36.2-76.2 | |
| Sex, no. (%) | .65 | ||
| Male | 30 (67) | 42 (62) | |
| Female | 15 (33) | 26 (38) | |
| CMV serologic status, no. (%) | .07 | ||
| Negative | 12 (27) | 9 (13) | |
| Positive | 33 (73) | 59 (87) | |
| Diagnosis, no. (%) | < .01 | ||
| AML | |||
| CR1, CR2 | 5 (11) | 15 (22) | |
| Advanced | 10 (22) | 24 (35) | |
| ALL | |||
| CR1, CR2 | 4 (9) | 6 (9) | |
| Advanced | 4 (9) | 9 (13) | |
| CML | |||
| CP | 7 (16) | 1 (1)† | |
| Advanced | 11 (24) | 4 (6) | |
| MDS | |||
| RA | 3 (7) | 3 (4) | |
| Advanced | 1 (2) | 4 (6) | |
| NHL | |||
| CR1, CR2 | 0 | 3 (4)† | |
| Advanced | 0 | 0 | |
| Duration from diagnosis to transplantation, mo | .06 | ||
| Median | 20 | 17 | |
| Range | 4-146 | 3-148 | |
| Duration of donor search, mo | < .01 | ||
| Median | 11 | 3 | |
| Range | 4-52 | 1-36 | |
| Conditioning, no. (%)‡ | .60 | ||
| TBI + Ara-C/G-CSF + CY | 36 (80) | 49 (72) | |
| TBI + CY | 5 (11) | 12 (18) | |
| TBI + α | 4 (9) | 7 (10) | |
| GVHD prophylaxis, no. (%) | < .01 | ||
| CsA | 0 | 3 (4) | |
| CsA + sMTX | 23 (51) | 65 (96) | |
| FK506 + sMTX | 21 (47) | 0 | |
| CsA + mPSL | 1 (2) | 0 | |
| G-CSF administration on first 7days, no. (%) | < .01 | ||
| Yes | 39 (87) | 68 (100) | |
| No | 6 (13) | 0 | |
| Year of transplantation, no. (%) | < .01 | ||
| 1997-1999 | 33 (73) | 9 (13) | |
| 2000-2003 | 12 (27) | 59 (87) | |
| Follow-up time, mo | .77 | ||
| Median | 14 | 25.2 | |
| Range | 1-100 | 1-68 | |
| Follow-up time in survivors, mo | < .01 | ||
| No. of evaluable patients | 21 | 52 | |
| Median | 59 | 26 | |
| Range | 13-100 | 4-68 | |
| No. of leukocytes for transplantation, × 107/kg | < .01 | ||
| Median | 33.0 | 2.47 | |
| Range | 6.6-50 | 1.1-5.29 | |
| No. of HLA-A, -B, and -DRB1 mismatches, no. (%) | < .01 | ||
| 0 | 39 (87) | 0 | |
| 1 | 6 (13) | 14 (21) | |
| 2 | 0 | 37 (54) | |
| 3 | 0 | 15 (22) | |
| 4 | 0 | 2 (3) | |
| Sex of donor/recipient, no. (%) | .22 | ||
| Male/male | 22 (49) | 21 (31) | |
| Female/female | 5 (11) | 10 (15) | |
| Female/male | 8 (18) | 21 (31) | |
| Male/female | 10 (22) | 16 (24) | |
| Extent of ABO match, no. (%) | .75 | ||
| Match | 16 (36) | 20 (29) | |
| Minor mismatch | 11 (24) | 20 (29) | |
| Major mismatch | 18 (40) | 28 (41) |
CMV indicates cytomegalovirus; AML, acute myelogenous leukemia; CR1, CR2, first and second complete remission; Advanced, patients in third complete remission, relapse, CML beyond chronic phase, or who had high-risk cytogenetics were classified as high risk; ALL, acute lymphoblastic leukemia; CML, chronic myelogenous leukemia; CP, chronic phase; MDS, myelodysplastic syndrome; RA, refractory anemia; NHL, non-Hodgkin lymphoma; TBI, total body irradiation; Ara-C, cytosine arabinoside; G-CSF, granulocyte colony-stimulating factor; CY, cyclophosphamide; CsA, cyclosporine; sMTX, short-term methotrexate; FK506, tacrolimus; and mPSL, methylprednisolone.
The chi-square test was used for categoric variables; the Mann-Whitney U test was used for continuous variables
One patient with CML in chronic phase and NHL in first complete remission received cord blood for the treatment of both diseases and was categorized as standard risk
All conditioning regimens included 12 Gy of TBI. In BMT group, 2 patients received TBI + CY + etoposide, 1 patient received TBI + Ara-C + antithymocyte globulin, and 1 patient received TBI + CY + antithymocyte globulin. In CBT group, 2 patients received TBI + G-CSF-combined Ara-C + one drug (fludarabine 30 mg/m2 × 3 days or antithymocyte globulin) and 5 patients received TBI + CY + one drug (etoposide in 3 patients, thiotepa in 1 patient, and antithymocyte globulin in 1 patient)